ReCor Medical has announced that the first patients, 292 total, have been enrolled in its Radiance-HTN study of its Paradise renal denervation device designed to treat hypertension.
The study, blind and randomized, has been created to be used with patients who are taking two or less medications compared to those with treatment-resistant hypertension taking a minimum of three different drugs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company raised a $15 million Series D round in April 2015, and it won an investigation device exemption from the FDA for a trial that took place in February.
ReCor does have some significant potential competition in the area, though. Boston Scientific, St. Jude Medical and Medtronic have each been involved with renal denervation innovation in the past, some failed attempts, but each are currently moving forward with clinical trials for various devices.
Photo: Screenshot via ReCor
